Listed since 2005
Products: SERTRALINE Hcl:1)4-(3,4-Dichlorophenyl)-1-Tetralone, 2)Racemic Sertraline Hcl. SOTOLOL Hcl: 1)4-(2-Chloroacetyl)Methane Sulfonanilide(4CAMS), 2)4-(2(Isopropylaminoacetyl)Methane Sulfonanilide(4IAMS) RESORCINOL Derivatives:1) 2-Chloro Resorcinol, 2)4-Chloro Resorcinol, Phloro Glucinol Dihydrate & Anhydrous. SOLMETEROL: 1)4-Phenyl-1-Butanol, 2)4-Phenyl Butyl Bromide, 3)N-(6-(4-Phenyl Butoxy) Hexy)Benzenemethanamine / PERINDOPRIL / TANDOLOPRIL:1) Indole-2-Carboxylic Acid, 2)(dl)Indoline-2-Carboxylic Acid, 3)(s)-(-)Indoline-2-Carboxylic Acid. PREGABALIN Intermediates. BETAXALOL: 4-(Benzyloxy)-2-Phenyl Ethanol. BENAZAPRIL: Alpha Teralone. MODAFINIL: Diphenyl Methyl Thio Acetamide. FINE CHEMICALS: 1) 4-Bromo Butyro Nitrile, 2) 3-Chloro Carbazole, 3) 3-Bromo Carbozole, 4) 3-Iodo Carbazole, 5) 2-Chloro-3',4'-Dihydroxyacetophenone. ITOPRIDE HCL INTERMEDIATES. PANTOPRAZOLE Intermediates. PRODUCT LIST: INTERMEDIATES: 4-(2-Chloroacetyl) Methane Sulfonanilide (4 Cams), 4-(2-Isopropylaminoacetyl) Methane Sulfonanilide (4-Iams), 4-(3',4 - Dichlorophenyl -l- Tetralone, Racemic Sertraline HCL, 4-(3-Chloropropyl), Morpholine HCL, 3,5-Disopropyl - 4-Hydroxy Benzoic Acid, 4-Chloro Resorcinol, Phloro Glucinol Dihydrate, 2-Chloro-3', 4'-Dihydroxyacetophenone, 2-Methoxy Phenoxy Ethylamine Hcl, Panto Prazole Intermediates. Export Brazil, Germany, United States, Belgium Europe, Latin America Import United Arab Emirates, Japan, China
Pragathi organics limited is a Bulk Drug Intermediates manufacturing company and Fine Chemicals. promoted by an eminent technocrat in the year 1994 in Bollaram, the Industrial area which is very close to Hyderabad, the Capital city of Bulk drug Industry in India. Pragathi Organics is producing important organic molecules that are in good demand in the pharmaceutical industry, which is one of the most sunrise industries in India. The Promoters of this Organization who are technically and financially competent enough are constantly striving hard to provide world class infrastructure for the accelerated growth of the unit. The R&D of the unit is working to introduce low volume high priced drug ntermediates so as to enhance the turnover and profitability. The unit which is presently doing a turnover of USD 2.27 millions per annum making necessary plans to grow big and contribute its share eventually to position India as the drug maker of the world.